DF Dent & Co. Inc. Reduces Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

DF Dent & Co. Inc. decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 147,147 shares of the company’s stock after selling 14,151 shares during the period. DF Dent & Co. Inc.’s holdings in Medpace were worth $48,887,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. R Squared Ltd bought a new stake in shares of Medpace in the fourth quarter worth approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace in the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp grew its position in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC raised its stake in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares during the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after buying an additional 29 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several research analyst reports. Leerink Partners initiated coverage on Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective for the company. Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday, March 24th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $376.30.

Medpace Trading Up 4.5 %

Shares of NASDAQ:MEDP opened at $311.23 on Thursday. Medpace Holdings, Inc. has a 12-month low of $289.01 and a 12-month high of $459.77. The company has a market cap of $9.48 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45. The stock has a 50 day moving average of $333.58 and a 200 day moving average of $338.33.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.